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Abstract 
Angiotensin (Ang)-(1-7) ameliorates vascular injury by increasing nitric oxide 
(NO)-bioavailability. Evidence that Ang-(1-7) attenuates the development of atherosclerosis 
through a NO-dependent mechanism is still missing. Moreover, it has been postulated that 
Ang-(1-7) may mediate its effects by other mechanisms than Mas receptor activation. 
To investigate Ang-(1-7)-dependent Mas receptor function, we treated apoE-KO and 
apoE/Mas-KO mice chronically with Ang-(1-7) (82 µg/kg per hour) or saline for 6 weeks. 
Flow mediated dilation (FMD), a measure for NO-dependent vasodilation and the most 
accepted prognostic marker for the development of atherosclerosis, was measured in vivo. 
Chronic Ang-(1-7) treatment improved FMD and attenuated the development of 
atherosclerosis in apolipoproteinE (apoE)-KO but not in apoE/Mas-KO mice. These effects 
were accompanied by increased aortic nitrite and cGMP levels. To test whether Ang-(1-7) 
modulates atherosclerosis through a NO-dependent mechanism, apoE-KO mice were treated 
with the NO synthase inhibitor L-NAME (20mg/kg/day) in the presence or absence of 
Ang-(1-7). L-NAME treatment reduced aortic nitrite content and increased blood pressure 
and exaggerated atherosclerosis compared to untreated apoE-KO mice. In L-NAME treated 
apoE-KO mice, chronic Ang-(1-7) treatment did not increase aortic nitrite content and 
consequenty showed no effect on blood pressure and the development of atherosclerosis.  
The present study proves that Ang-(1-7) mediates its protective vascular effects through Mas 
receptor activation. Moreover, Ang-(1-7) mediated NO generation is essential for improving 
vascular function and prevents atherosclerosis in apoE-KO mice. 
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Introduction 
Atherosclerosis is one of the leading causes for cardiovascular mortality worldwide. 
Endothelial dysfunction, characterized by decreased nitric oxide (NO)-bioavailability is 
considered as a key event in the early stage of atherosclerosis. Animal and human studies 
provide profound evidence that activation of the angiotensin (Ang) II type 1 receptor by Ang 
II, exaggerates vascular injury by stimulating the recruitment of immune cells and vascular 
smooth muscle cells proliferation as well as impairing endothelial dysfunction [9]. In contrast, 
Ang-(1-7), recently recognized as another active metabolite of the renin angiotensin system 
which is cleaved from Ang I and Ang II by several endopeptidases and metalloproteinases 
like neprilysin and angiotensin converting enzyme 2 (ACE2) has been shown to counter 
regulate the pathophysiological effects of Ang II in cardiovascular diseases by activating its 
own receptor Mas [4,26]. Thus, chronic Ang-(1-7) infusion improved vascular function and 
attenuated the development of atherosclerosis by increasing NO-bioavailability, reducing 
vascular inflammation, immune cell response and VSMCs proliferation [6,10,17,18,28,16]. 
Accordingly, deletion of the Mas receptor leads to endothelial dysfunction and vascular 
inflammation [25]. Although many studies have indicated a beneficial effect of Ang-(1-7) on 
vascular function, it is still unknown whether the Ang-(1-7) mediated increase in 
NO-bioavailability affects directly the development of atherosclerosis. Moreover, recent 
studies have indicated that Ang-(1-7) mediates its effects not solely via the Mas receptor but 
also via the Ang II Typ2 receptor [18,22]. To investigate this mechanism and to clarify the 
role of Mas as natural receptor of Ang-(1-7) in the development of atherosclerosis, we 
generated apolipoproteinE/Mas receptor double deficient (apoE/Mas-KO) mice and fed high 
fat, cholesterol enriched western-type diet (WD) for 12 weeks. 
Materials and Methods 
Animals 
All animal experimental investigations were in accordance with the federal state 
authority (Landesamt fuer Natur-, Umwelt- und Verbraucherschutz Nordrhein Westfalen; 
reference: AZ. 8.87-50.10.34.08.216 and AZ 84–02.04.2012.A250) and performed according 
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to the guidelines from Directive 2010/63/EU of the European Parliament on the protection of 
animals used for scientific purposes. Mice were inspected daily for living environment and 
animation. The apoE-KO and apoE/Mas-KO mice were obtained from an in-house breed at 
the local animal care facility at Heinrich- Heine-Universität Düsseldorf. All mice were on a 
C57Bl/6 background. Littermates were used as controls. The animals were housed at 20°C to 
22°C temperature and a 12-hour day and night cycle with free access to water and food. 
Diet and drug administration 
6-week-old apoE-KO and apoE/Mas-KO mice on a C57BL/6 background were fed with WD 
food (Ssniff, Soest, Germany) (42% fat, 0.15% cholesterol) and allowed free access to tap 
water. After 6 weeks, mice were treated with either Ang-(1-7) (82 μg/kg/h) or saline via 
osmotic minipump (Alzet Model 1004) over 6 weeks as described previously [17]. The 
osmotic mini-pumps were replaced after 3 weeks.  
To examine whether Ang-(1-7) attenuates the development of atherosclerosis through a 
NO-dependent mechanism, apoE-KO mice were treated in the presence or absence of chronic 
Ang-(1-7) infusion with the NO synthase inhibitor L-NAME (20mg/kg/d) adapted after a 
protocol of Krowles et al.[7]. In detail, 8 weeks old apoE-KO mice were divided into three 
groups. Mice were fed with WD or WD + L-NAME (20mg/kg/d) or WD + L-NAME + 
Ang-(1-7) (82 μg/kg/h) via osmotic minipump (Alzet Model 1004) for additional 8 weeks. 
L-NAME was dissolved in water, and water were refreshed twice per week. 
Flow mediated dilation (FMD) 
FMD was measured on the day before termination. The details were described previously [15]. 
Mice were anesthetized with 2vol% isoflurane. Body temperature was kept at 37°C by using a 
heated examination table that was also equipped with ECG electrodes. Images of the femoral 
arteries (FA) in mice were obtained using the Visual Sonics imaging platform Vevo 2100 and 
a 30-70 MHz linear array micro scan transducer (Visual Sonics). Using Duplex ultrasound 
mode, the artery and the arterial blood flow are identified by pulsed-wave Doppler (PWD). 
During FMD-assessment, a vascular occluder was placed at the left limb to induce occlusion 
of the distal hind limb as an ischemic trigger. Inflation occlusion (5 minutes) was carried out 
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manually. Following hind limb ischemia, the cuff was deflated and femoral artery diameter 
measurements were continuously recorded for 3 min at 30 sec intervals. The heart rate and FA 
blood flow velocity were monitored by PWD.Quantification of the arterial lumen diameter 
was performed from recorded videos using an automated edge detection software (Brachial 
Analyzer, MIA, Iowa City) [15]. Percentage of FMD was calculated using the following 
formula: [(Diameter post-ischemic – Diameter baseline) ⁄ Diameter baseline] * 100. 
Measurement of vascular function in aortic rings 
Endothelium dependent vasorelaxation was measured in aortic rings from apoE-KO and 
apoE/Mas-KO mice treated either with Ang-(1-7) or saline. Aortic rings were mounted in a 
wire myography (Multi Myograph Model 610 M, Danish Myo Technology, Denmark) as 
described previously [3]. After equilibration, aortic rings were contracted with norepinephrine 
(1 μM; Sigma Aldrich) and dose response curves to carbachol were recorded. Isometric forces 
are expressed as a percentage of the maximal response to norepinehrine. 
Oil Red O Staining and quantification 
To quantify the extent of atherosclerotic lesions, the aortic arch was dissected from the 
mice as described previously [6]. The aortas were then incubated in 4% paraformaldehyde 
overnight. After removal of adventitia, tissues were stained with Oil Red O solution (ORO, 5 
g ORO powder in 1L methanol) histopathology staining method. Cleaned aortas were 
pretreated in 78% methanol for 5 minutes and then transfered to the fresh NaOH-ORO 
solution (1 ml NaOH: 3.5 ml ORO) for 90 minutes. After ORO staining, aortas were 
incubated in 78% methanol for 15 minutes and preserved in 1X PBS. To obtain photographs, 
aortas were pinned and photographed under a microscope and digital camera. The photos 
were captured by a camera (Coopix 4500, Nikon, Tokyo, Japan) with Carl Zeiss lens (426126 
Carl Zeiss, Jena, Germany) under a Leica microscope (Leica MZ6, Wetzlar, Germany). Fiji 
ImageJ software (Fiji Version 2.0.0) was used to measure the atherosclerotic lesions.  
Aortic cGMP measurement 
Immediately after termination of the experiment, aortic slices were cut and snap-frozen 
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in liquid nitrogen. To extract cGMP, samples were homogenized in 70% (v/v) ice-cold ethanol 
using a glass/glass homogenizer and then centrifuged (14 000x g, 15 min, 4°C). Supernatants 
were dried at 95°C and the cGMP content was measured by RIA. To standardize the different 
samples, protein pellets were dissolved in 0.1 M NaOH/0.1% sodium dodecyl sulfate (SDS) 
and protein content was determined using the bicinchoninic acid method (Uptima). 
Blood pressure measurement 
SBP was measured in conscious mice by tail-cuff method (BP-98A; Softron Co.) as 
described previously [20]. For habituation, mice were trained daily for five consecutive days 
prior to the experiment. Thereafter, ten measurements per mouse were recorded every day 
over a period of 8 weeks. 
Determination of aortic nitrite levels 
The descending aorta was excised, cleaned from adipose tissue and immediately snap frozen. 
Samples were weighed and homogenized in ice-cold sodium chloride (0.9%). Nitrite 
concentration in aortic tissue homogenates was assessed as previously described using HPLC 
(ENO20, Eicom, Dublin, Ireland) [21]. 
Statistical analysis 
Data have been expressed as mean ± SEM (n = number of animals or samples). Version 
5.0 of GraphPad Prism (San Diego, USA) was used for data analysis. The values for each 
parameter within a group are expressed as mean ± SEM. All data were analyzed by either 
Student’s t test or 2-way ANOVA, followed by Bonferroni’s multiple comparison post-hoc 
test, or Mann-Whitney U test after testing for normal distribution. Results were considered 
statistically significant for P<0.05. 
Results 
Ang-(1-7) improved endothelial dependent vasorelaxation via Mas receptor activation 
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Six weeks old, male apoE-KO and apoE/Mas-KO were fed WD for 12 weeks. After 6 
weeks, apoE-KO and apoE/Mas-KO were treated either with Ang-(1-7) (82 µg/kg per hour) 
or with saline via osmotic minipumps for additional 6 weeks. To investigate the role of 
Ang-(1-7) induced Mas receptor activation on endothelial-dependent vasodilation in 
apoE-KO and apoE/Mas-KO mice, vascular function was measured by flow-mediated dilation 
(FMD) in vivo and ex vivo in aortic wire myograph . Chronic Ang-(1-7) infusion significantly 
increased FMD (FMD: 17.5±0.6 vs. 8.7±0.4%, n=5-11) and improved endothelial dependent 
vasorelaxation in aortic rings of apoE-KO but not of apoE/Mas-KO mice (FMD: 9.0±1.2 vs. 
8.0±0.7%, n=5; aortic rings) (Fig. 1a and b). This improvement was caused by an increase in 
Ang-(1-7) mediaded vascular NO-bioavailability as nitrite (3.5±0.4 vs. 2.3±0.4µM, n=7-8) 
and cGMP content (3.0±0.4 vs. 1.4±0.2pmol/l, n=7-8), both markers for NO generation were 
significantly enhanced in aortas of Ang-(1-7) treated apoE-KO mice (Fig. 2a and b).  
Chronic Ang-(1-7) treatment attenuates the development of atherosclerosis in apoE-KO 
but not in apoE/Mas-KO mice 
To investigate whether improved endothelial vascular function was also associated with 
reduced atherosclerosis, we analyzed atherosclerotic lesions in the aortic arch. Accordingly, 
Ang-(1-7) reduced atherosclerosis in apoE-KO (relative lesion area: 11.2±1.0 vs. 24.3±2.1%; 
specific lesion area: 2.9±0.3 vs. 6.6±0.8mm2, n=6-10) but not in apoE/Mas-KO mice (relative 
lesion area: 37.0±4.5 vs. 37.0±2.9%; specific lesion area: 12.3±1.5 vs. 11.5±1.1mm2, n=9) 
(Fig. 3). These results demonstrated that Ang-(1-7) mediates its protective vascular effects 
solely through the Mas receptor activation.  
Ang-(1-7) attenuated atherosclerosis through a nitric oxide mediated mechanism 
To examine whether Ang-(1-7) attenuates the development of atherosclerosis through a 
NO-dependent mechanism, apoE-KO mice were treated in the presence or absence of chronic 
Ang-(1-7) infusion with the NO synthase inhibitor L-NAME (20mg/kg/d) similar to a 
protocol of Krowles et al.[7]. As expected, chronic L-NAME treatment increased systolic 
blood pressure (apoE-KO 118±2mmHg vs. apoE-KO+L-NAME 125±3mmHg vs. 
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apoE-KO+L-NAME+Ang-(1-7) 127±2mmHg, n=7-9) and reduced aortic nitrite levels 
significanly (1.4±0.2 vs. 0.8±0.1, n=6) (Figure 4a and b). Ang-(1-7) infusion did not affect 
blood pressure and aortic nitrite levels in L-NAME treated apoE-KO mice(0.8±0.1 vs. 
0.9±0.1, n=6). Moreover, chronic Ang-(1-7) infusion did not reduce atherosclerotic plaques in 
L-NAME treated apoE-KO mice (relative lesion area: 6.5±1.4 vs. 11.8±1.3 vs. 10.9±1.2%; 
specific lesion area: 1.5±0.3 vs. 3.1±0.4 vs. 3.1±0.4mm2, n=7-9) demonstrating an essential 
contribution of NO on the beneficial effects of Ang-(1-7) in atherosclerosis (Figure 4c).  
Discussion 
In the present study, we show for the first time that Ang-(1-7) improves vascular function 
and attenuates the development of atherosclerosis via Mas receptor activation. Recently, it has 
been demonstrated that ACE2 deficiency, one of the key enzymes in Ang II degradation and 
an important member of the ACE2/Ang-(1–7)/Mas axis, causes vascular dysfunction and 
exaggerates the development of atherosclerosis [19]. However, since ACE2 deficiency also 
leads to an accumulation of the proatherogenic metabolite Ang II, the role of Ang-(1–7) and 
the Mas receptor, in the regulation of these effects was still unclear [5]. Vascular function was 
measured in vivo by FMD, the most widely used and accepted prognostic marker for the 
development of atherosclerosis in humans and ex vivo by aortic ring myography [23]. And 
indeed, administration of Ang-(1-7) not only improved endothelial dysfunction, but also 
attenuated atherosclerosis in apoE-KO but not in apoE/Mas-KO mice. Although there are 
several reports suggesting non-specific actions of Ang-(1-7), here, we  clearly demonstrate 
that Ang-(1-7) mediates its vasoprotective effects solely via Mas receptor activation 
[10,17,18,27].  
In humans, FMD is a widely accepted measure for NO-bioavailability and 
NO-dependent vasodilation [12]. By using an additional ex vivo method for measuring 
NO-dependent vasodilation, we confirmed that the improvement observed in FMD by 
Ang-(1-7) reflects an improvement in NO dependent endothelial vasorelaxation in Ang-(1-7) 
treated apoE-KO mice. Moreover, we also show that Ang-(1-7) increased NO dependent 
cGMP generation in aortas of apoE-KO mice underlining the important function of the 
Ang-(1-7)/Mas receptor axis in preventing vascular injury [17,18]. In this regard, several 
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studies have shown that Ang-(1-7) mediated Mas receptor activation induces NO generation 
through a phosphoinositide 3 kinase (PI3K)/AKT dependent mechanism leading to eNOS by 
phosphorylation at serine 1177 [1,2,14,17,24]. In addition, it has been shown that Ang-(1-7) 
decreased NO degradation by reducing ROS production. Ang-(1-7) decreases the expression 
levels of NOX2 and p47phox and inhibits MAK kinase signalling leading to increased NO 
bioavailability and improved vascular function [8,10,13,24,28]. 
Based on the observation that reduced endothelial NO generation accelerated 
atherosclerosis, we tested the impact of Ang-(1-7) mediated NO generation on the 
development of atherosclerosis [7]. Here, we demonstrate that Ang-(1-7) attenuates the 
development of atherosclerosis through an NO-dependent mechanism, as inhibition of NO 
synthase by L-NAME inhibits the beneficial effects of Ang-(1-7). These results are in 
accordance to previous studies showing that Mas receptor deletion accelerates endothelial 
dysfunction by reducing NO bioavailability [11,25]. 
Taken together, the present study clearly demonstrates that Mas receptor induced NO 
generation plays a key role in the improvement of vascular function and protects against the 
development of atherosclerosis. As recent studies have also shown a substantial effect of the 
Mas receptor on immune cell function and vascular inflammation, further studies need to 
evaluate whether these effects are also mediated through a NO-dependent mechanism [6].   
Legends 
Fig. 1 Ang-(1-7) improves endothelial dependent vasorelaxation through Mas receptor 
activation. a Ang-(1-7) increased flow mediated dilation (FMD) in apoE-KO but not in 
apoE/Mas-KO. *P＜0.05, ** P＜0.01, *** P＜0.001. Results are represented as mean ± SEM. 
b Ang-(1-7) improved endothelial depedent vasorelaxation to carbachol in aortic rings of 
apoE-KO but not of apoE/Mas-KO mice. ApoE-KO (n=11) vs. apoE/Mas-KO (n=11) *P＜
0.05, **P＜0.01, ***P＜0.001; apoE-KO (n=11) vs. apoE-KO vs. apoE-KO[Ang-(1-7)] 
(N=6) #P<0.05; apoE-KO vs. apoE/mas-KO[Ang-(1-7)] +P<0.05, ++P<0.01; apoE/Mas-KO 
vs. apoE/mas-KO[Ang-(1-7)] P=not significant. Results are represented as mean ± SEM. 
Fig. 2 Ang-(1-7) improves NO bioavailability in apoE-KO mice. a and b Chronic Ang-(1-7) 
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treatment increased aortic nitrite concentration and cGMP levels in apoE-KO. *P＜0.05, **P
＜0.01. Results are represented as mean ± SEM. 
Fig. 3 Ang-(1-7) attenuates the development of atherosclerosis through Mas receptor 
activation. Ang-(1-7) decreased the relative and specific atherosclerotic lesion area in 
apoE-KO but not in apoE/Mas-KO. Representative pictures of Oil-red O stained aortic arches 
are shown. The distance between the digital calipers is 7 mm. **P＜0.01, ***P＜0.001. 
Results are represented as mean ± SEM. 
Fig. 4 . Ang-(1-7) attenuates atherosclerosis through a NO dependent mechanism. a and b 
L-NAME increased SBP and decreased aortic nitrite levels in apoE-KO. During L-NAME 
treatment, Ang-(1-7) failed to increase aortic nitrite levels. c Chronic L-NAME treatment 
accelerated atherosclerotic plaques. During L-NAME treatment, Ang-(1-7) failed to reduce 
atherosclerotic lesions. *P＜0.05. Results are represented as mean ± SEM. 
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